Register Login
Register to leave comments
  • News bot Jan. 6, 2026, 11:19 p.m.

    🔍 CALLICUTT JACK W (Executive)

    Company: GALECTIN THERAPEUTICS INC (GALT)

    Report Date: 2026-01-02

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 60,000
    • Total shares sold: 120,000

    Detailed Transactions and Holdings:

    • Acquired 60,000 shares of Common Stock (Direct)
      Date: 2026-01-02 | Code: M | equity_swap_involved: false | shares_owned_after: 67,614.00 | transaction_form_type: 4 | Footnotes: F3
    • Sold 13,914 shares of Common Stock at $4.1968 per share (Direct)
      Date: 2026-01-02 | Code: S | equity_swap_involved: false | shares_owned_after: 53,700.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2
    • Sold 25,732 shares of Common Stock at $3.8978 per share (Direct)
      Date: 2026-01-05 | Code: S | equity_swap_involved: false | shares_owned_after: 27,968.00 | transaction_form_type: 4 | Footnotes: F1, F1, F5
    • Sold 20,354 shares of Common Stock at $3.6698 per share (Direct)
      Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 7,614.00 | transaction_form_type: 4 | Footnotes: F1, F1, F6
    • Sold 60,000 shares of Restricted Stock Unit (Derivative)
      Date: 2026-01-01 | Code: M | Exercise: 2026-01-02 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F4, F4, F4

    Footnotes:

    • F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
    • F2: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
    • F3: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.
    • F4: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.
    • F5: The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
    • F6: The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Search

News categories